Frequency and Clinical Outcome of Respiratory Viral Infections and Mixed Viral-bacterial Infections in Children With Cancer, Fever and Neutropenia

2012 ◽  
Vol 31 (9) ◽  
pp. 889-893 ◽  
Author(s):  
Juan P. Torres ◽  
Yenis Labraña ◽  
Carolina Ibañez ◽  
Pilar Kasaneva ◽  
Mauricio J. Farfán ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Bacterial Infections ◽  
Viral Infections ◽  
Children With Cancer ◽  
Respiratory Viral Infections

Prevalence and clinical outcome of respiratory viral infections among children with cancer and febrile neutropenia

2019 ◽  
Vol 36 (6) ◽  
pp. 330-343 ◽  
Author(s):  
Jagdish Prasad Meena ◽  
Megha Brijwal ◽  
Rachna Seth ◽  
Aditya Kumar Gupta ◽  
Jyoti Jethani ◽  
...  
Keyword(s):  
Febrile Neutropenia ◽  
Clinical Outcome ◽  
Viral Infections ◽  
Children With Cancer ◽  
Respiratory Viral Infections

scholarly journals The Key Roles of Interferon Lambda in Human Molecular Defense against Respiratory Viral Infections

Pathogens ◽  
2020 ◽  
Vol 9 (12) ◽  
pp. 989
Author(s):  
Alexey A. Lozhkov ◽  
Sergey A. Klotchenko ◽  
Edward S. Ramsay ◽  
Herman D. Moshkoff ◽  
Dmitry A. Moshkoff ◽  
...  
Keyword(s):  
Immune Response ◽  
Bacterial Infections ◽  
Viral Infections ◽  
Public Health Problem ◽  
Negative Influence ◽  
Epithelial Tissue ◽  
Major Public Health Problem ◽  
Type Iii ◽  
Respiratory Viral Infections ◽  
Type Iii Ifn

Interferons (IFN) are crucial for the innate immune response. Slightly more than two decades ago, a new type of IFN was discovered: the lambda IFN (type III IFN). Like other IFN, the type III IFN display antiviral activity against a wide variety of infections, they induce expression of antiviral, interferon-stimulated genes (MX1, OAS, IFITM1), and they have immuno-modulatory activities that shape adaptive immune responses. Unlike other IFN, the type III IFN signal through distinct receptors is limited to a few cell types, primarily mucosal epithelial cells. As a consequence of their greater and more durable production in nasal and respiratory tissues, they can determine the outcome of respiratory infections. This review is focused on the role of IFN-λ in the pathogenesis of respiratory viral infections, with influenza as a prime example. The influenza virus is a major public health problem, causing up to half a million lethal infections annually. Moreover, the virus has been the cause of four pandemics over the last century. Although IFN-λ are increasingly being tested in antiviral therapy, they can have a negative influence on epithelial tissue recovery and increase the risk of secondary bacterial infections. Therefore, IFN-λ expression deserves increased scrutiny as a key factor in the host immune response to infection.

scholarly journals Clinical Outcome of Herbal Medicine-related Problems for Respiratory Viral Infections

2021 ◽  
Vol 10 (4) ◽  
pp. 138-143
Author(s):  
Yousef Ahmed Alomi ◽  
Ghadeer Alhazmi ◽  
Murouj Almaghrabi ◽  
Ghaida Alzahrani ◽  
Mohammad Almatrafi
Keyword(s):  
Herbal Medicine ◽  
Clinical Outcome ◽  
Viral Infections ◽  
Respiratory Viral Infections

scholarly journals Probiotics for prevention of acute respiratory infections in children: therapeutic potential.

2021 ◽  
pp. 254-260
Author(s):  
Irina N. Zakharova ◽  
Narine G. Sugyan
Keyword(s):  
Respiratory Tract ◽  
Bacterial Infections ◽  
Viral Infections ◽  
Therapeutic Potential ◽  
Respiratory Infections ◽  
Short Chain Fatty Acids ◽  
Acute Respiratory Infections ◽  
Human Respiratory Tract ◽  
Local Immunity ◽  
Respiratory Viral Infections

Acute respiratory viral infections represent a group of clinically, pathomorphologically similar acute inflammatory respiratory diseases that manifest by fever, a runny nose, sneezing, cough, sore throat, a general feeling of ill health of varying severity. Activation of latent, persistent infections of viral and/or bacterial origin may occur in recurrent respiratory infections. Decreased production of local immunity contributes greatly to the development of viral and bacterial infections, persistence of pathogenic micro-organisms. Intestinal microflora can directly or indirectly affect the human respiratory tract through increased production of cytokines, short-chain fatty acids. In recent years, there has been a scientific interest in the therapeutic potential of probiotics for the prevention of acute respiratory viral infections. Earlier studies have shown a positive effect of probiotics on the respiratory tract with a view to prevent and reduce the incidence and severity of respiratory infectious diseases by expending the number of IgA secreting cells in the bronchial mucosa. Studies showed that the use of probiotics can reduce the incidence of acute respiratory infections, duration of fever, cough, and the need for antibacterial agents in children. Peptidoglycans and muramyl peptides that are constituents of the bacterial cell wall have antiviral activity. Probiotics can also inhibit virus attachment through a process of competing for the specific receptors. The regeneration of the mucous membrane is enhanced by the ability of mucin to prevent the virus from attaching to epithelial cells and suppress virus replication. The antiviral effect of probiotics may be caused by the ability to produce antimicrobial peptides, dehydrogenases and NOs. Probiotics can modulate the functions of epithelial and dendritic cells, CD4 +, CD8 + T lymphocytes, NK cells, stimulate the synthesis of secretory immunoglobulins, helping to neutralize the virus.

scholarly journals Prevention of acute respiratory viral infections and influenza in children during the peaks of seasonal morbidity: the results of the international double-blind placebo-controlled randomized clinical trial

2020 ◽  
Vol 65 (3) ◽  
pp. 109-120
Author(s):  
N. A. Geppe ◽  
A. V. Gorelov ◽  
O. V. Shamsheva ◽  
I. G. Sitnikov ◽  
E. P. Sitnikova ◽  
...  
Keyword(s):  
Placebo Group ◽  
Bacterial Infections ◽  
Viral Infections ◽  
Group Versus ◽  
Study Drug ◽  
Preventive Therapy ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Respiratory Viral Infections

The authors conducted an international multicenter double-blind, placebo-controlled clinical study to obtain additional data on the efficacy and safety of a 12-week course of Anaferon for children for the prevention of acute respiratory viral infections (ARVI), including influenza, in children during the rise in seasonal morbidity (RCT of the Ministry of Health of the Russian Federation: №356 dated June 29, 2017; ClinicalTrials.gov Identifier: NCT03301155).Materials and methods. The study involved 1,036 children (1 month – 6 years 11 months 29 days) during two epidemiological seasons. The patients were divided into 2 groups: 528 patients received Anaferon for children 1 tablet a day for 12 weeks, 508 patients received placebo according to Anaferon for children scheme. The primary end point was the duration of the period from the first dose of the drug until manifestation of ARVI/influenza. Additional end points were percentage of children not falling with ARVI/influenza during 4-, 8- and 12-week course of preventive therapy; percentage of children with respiratory or ear-nose-throat bacterial infections requiring antibiotics within 12 week; percentage of children hospitalized with ARVI/influenza or their complications within 12 week. To assess safety, the authors analyzed the presence and nature of the adverse events (AEs), their severity, connection with the medication, outcome. The authors used the following statistical methods: calculation of hazard ratio, median time to the manifestation of symptoms of ARVI / influenza, 95% confidence intervals.Results. The Intention-to-treat (ITT) and Per Protocol [РР] analysis included the data of 1,021 [975] patients: 520 [494] – Anaferon for children group and 501 [481] –Placebo group. The average duration of the period from the first dose of the drug to the development of ARVI/influenza symptoms obtained as a result of the analysis of the statistical model was 428.8 [434.1] days for Anaferon for children group, that is 1.5 times higher than in Placebo group (275.8 [274.9] days; p=0.001 [p=0.0009]). The percentage of children without ARVI/influenza was 99.2% [99.2%] in Anaferon for children group (versus 90.2% [90.0%] in Placebo group; p=0.0003 [p=0.0003]) within 4 weeks, 92.7% [92.3%] (versus 82.8% [82.7%]; p=0.0003 [p=0.0003]) within 8 weeks, and 81.5% [81.8%] (versus 73.4% [73.4%], respectively; p=0.0021 [p=0.0021]). None of the patients was hospitalized for ARVI/influenza or complications. The frequency of AEs in Anaferon for children and Placebo groups had no differ. No one AE definitely related to the study drug was registered.Conclusion. The results confirm the efficacy and safety of a 12-week course of Anaferon for children to prevent ARVI and influenza during seasonal rise of morbidity in children.

Respiratory Viral Infections and Coinfections in Children With Cancer, Fever and Neutropenia

2016 ◽  
Vol 35 (9) ◽  
pp. 949-954 ◽  
Author(s):  
Juan Pablo Torres ◽  
Verónica De la Maza ◽  
Lisette Kors ◽  
Milena Villarroel ◽  
Paula Piemonte ◽  
...  
Keyword(s):  
Viral Infections ◽  
Children With Cancer ◽  
Respiratory Viral Infections

scholarly journals Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit

2000 ◽  
Vol 26 (10) ◽  
pp. 1097-1102 ◽  
Author(s):  
BNA Crooks ◽  
CE Taylor ◽  
AJL Turner ◽  
HKE Osman ◽  
M Abinun ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Viral Infections ◽  
Immune Deficiencies ◽  
Respiratory Viral Infections
Sign in / Sign up

Export Citation Format

Share Document